Previous 10 | Next 10 |
Genmab is one of my top picks in healthcare. The company expects to report impressive growth over the remainder of 2022 and beyond. Genmab has an imposing pipeline of proprietary and partnered programs that should provide additional growth opportunities. Genmab recently publicized...
Danish biotech firm Genmab A/S (GMAB) said on Thursday it had begun a new arbitration and was seeking an award of $405M under its license agreement with Johnson & Johnson's (JNJ) unit Janssen Biotech for cancer drug, Darzalex. Genmab is locked in a legal battle with JNJ ove...
-- Interim results of tisotumab vedotin plus pembrolizumab from Phase 1b/2 innovaTV 205 trial, showing 41% objective response rate in first-line patients with recurrent or metastatic cervical cancer (r/mCC), to be presented in an oral session -- -- Additional poster presentati...
-- Interim results of tisotumab vedotin plus pembrolizumab from Phase 1b/2 innovaTV 205 trial, showing 41% objective response rate in first-line patients with recurrent or metastatic cervical cancer (r/mCC), to be presented in an oral session -- -- Additional poster presentati...
Multiple epcoritamab (DuoBody ® -CD3xCD20) poster presentations highlighting data in a variety of treatment settings and hematologic malignancies Oral presentation of tisotumab vedotin first-line combination study in patients with recurrent or metastatic cervical ca...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Johnson & Johnson (NYSE: JNJ ) stock is up for 2022 in a down market Credit goes to its medical devices and anti-cancer drug Darzalex JNJ’s dividend has been rising for six decades, making it a safe st...
Multiple epcoritamab (DuoBody ® -CD3xCD20) studies will be presented showcasing preliminary efficacy and safety findings in a variety of patient populations in need of treatment options Several abstracts evaluating Genmab owned and partnered programs accepted for pr...
The following slide deck was published by Genmab A/S in conjunction with their 2022 Q1 earnings call. For further details see: Genmab A/S 2022 Q1 - Results - Earnings Call Presentation
Image source: The Motley Fool. Genmab A/S (NASDAQ: GMAB) Q1 2022 Earnings Call May 11, 2022 , 12:00 p.m. ET Operator Continue reading For further details see: Genmab A/S (GMAB) Q1 2022 Earnings Call Transcript
Genmab A/S (GMAB) Q1 2022 Earning Conference Call May 11, 2022 12:00 PM ET Company Participants Jan van de Winkel - President and Chief Executive Officer Anthony Pagano - Chief Financial Officer Conference Call Participants Peter Virgil - Citigroup James Gordon - JPMorgan Wimal Kapadia - Bern...
News, Short Squeeze, Breakout and More Instantly...
A look at the top 10 most actives in the United States Innovative Eyewear Inc. (LUCY) rose 78.0% to $0.58749 on volume of 130,454,575 shares Ocean Power Technologies Inc. (OPTT) rose 29.6% to $0.2073 on volume of 51,927,154 shares Cosmos Health Inc. (COSM) rose 64.9% to $1.12 on volume of...
Company Announcement Positive CHMP opinion based on results from the Phase 1/2 EPCORE ® NHL-1 study FL is the second most common type of NHL and accounts for approximately 20-30 percent of all global cases If approved, epcoritamab (TEPKINLY ® ...
2024-06-27 09:00:08 ET Kaveri Pohlman from BTIG issued a price target of $47.00 for GMAB on 2024-06-27 07:34:00. The adjusted price target was set to $47.00. At the time of the announcement, GMAB was trading at $25.67. The overall price target consensus is at $41.80 with...